Apellis Pharmaceuticals stock is oversold, possible buying opportunity.

From Nasdaq.: 2025-03-31 16:28:00

Legendary investor Warren Buffett advises being fearful when others are greedy and greedy when others are fearful. One way to measure fear in a stock is through the Relative Strength Index (RSI), which scales momentum from 0 to 100. Apellis Pharmaceuticals Inc (APLS) recently hit an RSI of 26.7, entering oversold territory at $21.89 per share, compared to the S&P 500 ETF’s RSI of 39.2. This could signal a buying opportunity as selling pressure may be easing. APLS has a 52-week range of $21.725 to $59.91, currently trading at $21.73. Check out other oversold stocks for potential opportunities.



Read more at Nasdaq.: Apellis Pharmaceuticals is Now Oversold (APLS)